Recurrent Islet Cell Carcinoma

14 clinical trials · Condition

Record	Firm	Date
Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors (NCT02259725)	University of Southern California	2016-08-16
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer (NCT02273752)	Emory University	2014-11-01
Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors (NCT02108782)	Academic and Community Cancer Research United	2014-10-01
Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery (NCT02031536)	ECOG-ACRIN Cancer Research Group	2014-04-10
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors (NCT01824875)	ECOG-ACRIN Cancer Research Group	2013-08-08
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors (NCT01525082)	Shaheen Shagufta	2012-12-01
Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery (NCT01465659)	Northwestern University	2011-12-12
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors (NCT01155258)	University of Southern California	2010-06-01
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors (NCT00131911)	National Cancer Institute (NCI)	2005-06-01
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (NCT00655655)	Mayo Clinic	2004-12-01
Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors (NCT00084461)	National Cancer Institute (NCI)	2004-03-01
Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma (NCT00093782)	National Cancer Institute (NCI)	2003-12-01
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors (NCT00075439)	National Cancer Institute (NCI)	2003-12-01
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu (NCT00004074)	National Cancer Institute (NCI)	1999-08-01

Track Recurrent Islet Cell Carcinoma automatically

Every clearance here is in the API, with alerts when new ones post.